Pramod K Mistry Selected Research

eliglustat

1/2023	Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
12/2021	Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
1/2021	Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
1/2020	Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
1/2019	Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
1/2018	Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
11/2017	Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
2/2015	Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pramod K Mistry Research Topics

Disease

56	Gaucher Disease (Gaucher's Disease) 05/2023 - 09/2002
6	Neoplasms (Cancer) 10/2022 - 05/2010
5	Splenomegaly 09/2020 - 07/2008
4	Lysosomal Storage Diseases (Lysosomal Storage Disease) 09/2022 - 02/2013
4	Rare Diseases (Rare Disease) 01/2022 - 01/2011
4	Inflammation (Inflammations) 12/2021 - 01/2013
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 11/2014
3	Metabolic Bone Diseases (Osteopenia) 01/2021 - 01/2011
3	Liver Cirrhosis (Hepatic Cirrhosis) 09/2020 - 11/2014
2	Osteonecrosis (Kienbock's Disease) 01/2023 - 08/2012
2	Melanoma (Melanoma, Malignant) 12/2021 - 01/2018
2	Ataxia (Dyssynergia) 10/2021 - 02/2013
2	Niemann-Pick Diseases (Niemann Pick Disease) 09/2020 - 01/2019
2	Pulmonary Hypertension 01/2019 - 09/2002
2	Disease Progression 01/2018 - 04/2016
2	Paraproteinemias (Monoclonal Gammopathy) 01/2018 - 02/2016
2	Parkinson Disease (Parkinson's Disease) 10/2017 - 04/2016
2	Hyperferritinemia 01/2013 - 07/2010
2	Pancreatitis 05/2012 - 11/2009
1	Pain (Aches) 01/2023
1	Hepatic Encephalopathy 04/2022
1	Ascites 04/2022
1	Cytopenia 04/2022
1	Neuroinflammatory Diseases 01/2022
1	Seizures (Absence Seizure) 10/2021
1	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 10/2021
1	Myoclonus (Nocturnal Myoclonus) 10/2021
1	Neurologic Manifestations (Neurological Manifestations) 10/2021
1	COVID-19 01/2021
1	Hemorrhage 09/2020
1	Wasting Syndrome (Wasting Disease) 12/2019
1	Congenital chloride diarrhea 12/2019
1	Fibrosis (Cirrhosis) 09/2019
1	Hemorrhagic Shock 01/2019
1	Alcoholic Fatty Liver 01/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2019
1	Dyslipidemias (Dyslipidemia) 01/2019
1	Acute Kidney Injury (Acute Renal Failure) 01/2019
1	Multiple Myeloma 01/2018
1	Iron Overload 01/2018
1	Monoclonal Gammopathy of Undetermined Significance 01/2018
1	Parkinsonian Disorders (Parkinsonism) 01/2017
1	Anemia 01/2017
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Hepatomegaly 11/2016
1	Dementia (Dementias) 04/2016

Drug/Important Bio-Agent (IBA)

18	Glucosylceramides (Glucocerebrosides)IBA 10/2022 - 04/2010
16	Glucosylceramidase (Glucocerebrosidase)IBA 01/2020 - 10/2004
13	Biomarkers (Surrogate Marker)IBA 01/2023 - 04/2011
13	LipidsIBA 04/2022 - 06/2010
10	sphingosyl beta-glucosideIBA 01/2022 - 10/2011
10	AcidsIBA 12/2021 - 12/2010
9	GlucosidasesIBA 12/2021 - 12/2010
8	eliglustatIBA 01/2023 - 02/2015
8	chitotriosidaseIBA 12/2021 - 12/2010
6	EnzymesIBA 01/2022 - 01/2011
5	Hemoglobins (Hemoglobin)IBA 01/2021 - 07/2010
5	imiglucerase FDA Link 09/2017 - 02/2009
3	AntigensIBA 01/2020 - 02/2016
2	SphingolipidsIBA 10/2022 - 04/2014
2	GlycosphingolipidsIBA 01/2022 - 10/2021
2	Glycoproteins (Glycoprotein)IBA 12/2021 - 01/2018
2	alglucerase FDA Link 09/2017 - 02/2009
2	HDL LipoproteinsIBA 04/2011 - 06/2010
1	AlbuminsIBA 04/2022
1	ceramide glucosyltransferaseIBA 01/2022
1	Lysergic Acid Diethylamide (LSD)IBA 01/2022
1	Scavenger Receptors (Scavenger Receptor)IBA 10/2021
1	miglustat (Zavesca)FDA Link 10/2021
1	Nucleic AcidsIBA 01/2021
1	Carbon MonoxideIBA 09/2020
1	Biosimilar PharmaceuticalsIBA 01/2020
1	SaposinsIBA 01/2020
1	SaltsIBA 12/2019
1	ProgranulinsIBA 09/2019
1	CathepsinsIBA 09/2019
1	ChemokinesIBA 09/2019
1	LigandsIBA 09/2019
1	cathepsin SIBA 09/2019
1	Cathepsin DIBA 09/2019
1	Insulin (Novolin)FDA Link 01/2019
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2019
1	AntioxidantsIBA 01/2019
1	Transaminases (Aminotransferases)IBA 01/2019
1	LeptinIBA 01/2019
1	Chemokine CCL18IBA 01/2018
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 11/2017
1	SynucleinsIBA 10/2017
1	Indicators and Reagents (Reagents)IBA 04/2016
1	Levodopa (L Dopa)FDA LinkGeneric 04/2016
1	Immunoglobulins (Immunoglobulin)IBA 02/2016

Therapy/Procedure

23	Therapeutics 05/2023 - 09/2002
18	Enzyme Replacement Therapy 05/2023 - 09/2002
8	Splenectomy 04/2022 - 07/2008
3	Enzyme Therapy 12/2021 - 02/2009
2	Liver Transplantation 04/2022 - 11/2014
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 04/2022
1	Transjugular Intrahepatic Portasystemic Shunt 04/2022
1	Extracorporeal Membrane Oxygenation 01/2019
1	Lung Transplantation 01/2019